NRX Pharmaceuticals, Inc. (NRXP) Dividend History

Company News

• NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

  NRx Pharmaceuticals announced that the FDA has granted a filing fee waiver for its upcoming NRX-100 (preservative-free ketamine) New Drug Application to treat suicidal depression. The waiver will enable the company to complete the NDA filing with its current resources.

  Benzinga
• NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors

  The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.

  Zacks Investment Research
• 3 Penny Stocks Under $3 To Watch Right Now

  Penny stocks under $3 to watch this week. The post 3 Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: HNST
• Why Shares of Bausch Health Companies Dropped 54.4% This Week

  A patent-court loss sent investors scurrying to the exits.

  The Motley Fool

  Featured Companies: BHC BLCO
• NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

  RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute for Strategic Management of Tel Aviv University. His remarks were summarized in the Hebrew language edition of Globes as follows:

  GlobeNewswire Inc.